Suboxone combines buprenorphine, a partial opioid agonist that reduces cravings and withdrawal, with naloxone, an opioid antagonist added to discourage injection misuse. Indivior markets the brand-name sublingual film, and the FDA approved the first generic buprenorphine/naloxone films from Mylan and Dr. Reddy's in 2018, followed by generics from Alvogen, Sandoz, and Amneal. Zubsolv, Bunavail, and Cassipa are competing brand-name buprenorphine/naloxone products with their own pricing.
The 2018 and 2019 generic launches collapsed Suboxone's price. Generic buprenorphine/naloxone now sells for roughly $30 to $300 per month depending on dose, pharmacy, and discount card, compared to $177 to $570 per month for brand-name Suboxone film. Congress removed the special DATA-Waiver (X-waiver) requirement for prescribers in the 2023 Consolidated Appropriations Act, so any practitioner with a standard DEA registration can now prescribe buprenorphine for opioid use disorder, which has widened access but has not changed the drug's price.
Federal law under the SUPPORT for Patients and Communities Act requires every state Medicaid program to cover FDA-approved medications for opioid use disorder, including Suboxone, buprenorphine mono-product, methadone, and naltrexone. Medicare covers Suboxone through Part D for self-administered prescriptions and through Part B at no cost to the beneficiary when dispensed through a Medicare-enrolled Opioid Treatment Program. Suboxone was not selected for the Inflation Reduction Act's first or second rounds of Medicare drug price negotiation, largely because generic competition already pushed the price down before Medicare needed to negotiate a Maximum Fair Price.
What Suboxone Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same suboxone can cost many times more at a hospital than at your local pharmacy:
2026 Suboxone Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Pharmacy counter, cash (generic) | $30 - $300/month | 2026 GoodRx and chain member-program pricing for generic buprenorphine/naloxone film or tablet |
| Pharmacy counter, cash (brand Suboxone) | $177 - $570/month | Brand film cash price without insurance in 2026 |
| Medicare Part D (2026) | $0 - $13/month, capped at $2,100/year | Formulary tier and plan vary the exact copay; Medicare-certified Opioid Treatment Programs bill separately under Part B at $0 to the patient |
| Commercial insurance with INSUPPORT card | As low as $5/month | Indivior manufacturer coupon caps copay at $5/month, up to $75/month in savings, commercial insurance only |
| Medicaid | $0 - $4/prescription | Mandatory coverage in all 50 states under the SUPPORT Act; many states waive the copay entirely for opioid use disorder medications |
Retail prices reflect 2026 GoodRx and pharmacy chain member-program data. Medicaid and Medicare figures reflect standard 2026 program design; your exact cost depends on your specific plan and state.
Source: CMS Medicare Part D 2026 benefit design, Medicaid.gov MAT coverage mandate, Indivior INSUPPORT, GoodRx
Why Hospitals Charge So Much
Emergency departments increasingly use buprenorphine induction protocols to start opioid use disorder treatment during an ED visit, a practice associated with better long-term retention in care. The buprenorphine/naloxone film itself costs only a few dollars per dose to acquire, but the itemized bill for an ED-initiated induction typically bundles a facility fee, an evaluation and management charge, and nursing observation time, pushing the total charge for that visit to $300 to $1,200 or more even though the drug charge is a small fraction of that total.
Inpatient psychiatric or detox units that administer Suboxone as part of a supervised withdrawal-management stay bill the drug at facility rates similar to any other inpatient medication, with markups for pharmacy handling and nursing administration layered on top of the low acquisition cost. Patients who see Suboxone listed at $50 or more per dose on an inpatient itemized bill should request the National Drug Code and compare it against the generic's typical wholesale cost of a few dollars per film, since large gaps are common dispute targets.
HCPCS J-Codes: What Appears on Your Bill
Suboxone is usually a self-administered Medicare Part D drug with no J-code involved. The exception is Medicare-certified Opioid Treatment Programs (OTPs), which bill Medicare Part B using bundled weekly payment codes that include a buprenorphine/naloxone drug component reported under HCPCS J-codes based on the buprenorphine dose dispensed that week.
HCPCS J-codes for Suboxone| Code | Description | What to look for |
|---|
| J0572 | Buprenorphine/naloxone, oral, up to 3 mg buprenorphine | Used for low-dose maintenance or early induction weeks in an OTP bundle |
| J0573 | Buprenorphine/naloxone, oral, greater than 3 mg to 6 mg buprenorphine | Common maintenance-dose range; confirm the code matches the dose actually dispensed |
| J0574 | Buprenorphine/naloxone, oral, greater than 6 mg to 10 mg buprenorphine | Higher maintenance doses; verify this is not billed alongside a duplicate pharmacy claim |
| J0575 | Buprenorphine/naloxone, oral, greater than 10 mg buprenorphine | High-dose range; rare outside supervised OTP induction |
Medicare beneficiaries treated through a certified Opioid Treatment Program pay $0 for these bundled services under a 2020 policy that eliminated OTP cost-sharing. If you get a separate bill for the drug component while enrolled in an OTP, ask the program to confirm it billed the correct bundled G-code and J-code.
Source: CMS Opioid Treatment Program billing guidance, medicare.gov
Patient Assistance Programs
Indivior, the manufacturer of Suboxone, discontinued its income-based free-medication program for uninsured patients after generic competition drove the cash price down; that program is no longer active. What remains is a manufacturer coupon for commercially insured patients, plus the low generic cash price itself, which now functions as the main patient assistance program.
Patient assistance programs for Suboxone| Manufacturer program | Cost / Benefit | How to apply |
|---|
| Indivior INSUPPORT Suboxone Copay Savings Card | As low as $5/month copay, up to $75/month in savings, for commercially insured patients only | insupport.com |
| NeedyMeds Drug Discount Card | Variable discount on generic buprenorphine/naloxone, accepted at most US pharmacies regardless of insurance status | needymeds.org |
| Federally funded Opioid Treatment Programs (sliding-scale) | Sliding-scale or free buprenorphine/naloxone for low-income, uninsured patients at SAMHSA-funded clinics | findtreatment.gov |
If you have Medicare, Medicaid, TRICARE, or VA benefits, the federal anti-kickback statute (42 U.S.C. Section 1320a-7b) bars you from using the Indivior manufacturer coupon. Use your Medicare Part D plan, Medicaid formulary tier copay, or a sliding-scale Opioid Treatment Program instead; generic buprenorphine/naloxone at $30 to $100 per month with a discount card is usually cheaper than pursuing a manufacturer patient assistance program application.
Source: Indivior INSUPPORT, NeedyMeds.org, SAMHSA findtreatment.gov
Medicare Part D
Suboxone is a Medicare Part D drug when self-administered outside a clinical setting. Most Part D plans place generic buprenorphine/naloxone on a low formulary tier with copays typically under $13 per month in 2026, and your total annual out-of-pocket spending across all Part D drugs is capped at $2,100 under the Inflation Reduction Act's redesign of the Part D benefit.
Medicare-certified Opioid Treatment Programs bill differently. Since 2020, Medicare Part B pays OTPs a bundled weekly rate that covers the buprenorphine/naloxone drug, dosing, and counseling, and the beneficiary owes $0 in cost-sharing for that bundle. Patients who get Suboxone from an OTP rather than a retail pharmacy should not see a separate Part D copay for the same prescription.
Prior authorization for Suboxone under Part D is less common than for newer branded drugs, since the generic is inexpensive, but some plans still require it for brand-name Suboxone film or higher-strength doses. Ask your prescriber's office to confirm your plan's formulary tier and any prior authorization or quantity-limit rules before you fill the prescription.
Common Suboxone Billing Errors
If your Suboxone bill looks high in 2026, check for these common issues before paying:
- Brand-name Suboxone film billed when the pharmacy actually dispensed the generic. Brand and generic have different NDC numbers and very different cash prices; confirm the label matches what your prescriber ordered.
- A Medicare Opioid Treatment Program billing a separate drug charge on top of the bundled weekly G-code payment, which should already include the buprenorphine/naloxone at $0 cost to you.
- A Medicaid pharmacy charging the standard $1 to $4 copay in a state that has waived cost-sharing for opioid use disorder medications; ask your state Medicaid agency whether the waiver applies to you.
- The INSUPPORT manufacturer coupon not applied at the pharmacy counter even though you have commercial insurance and are eligible; ask the pharmacist to rerun the claim with the card's BIN/PCN information.
- An emergency department bill that lists Suboxone at $50 or more per dose when the drug itself costs a few dollars; the balance is almost always a facility or observation fee, which can be itemized and appealed separately.
- A wrong HCPCS J-code (J0572 through J0575) reported for an Opioid Treatment Program claim, where the dose range on the claim does not match what was actually dispensed that week.
Frequently Asked Questions
Is there a generic version of Suboxone?
Yes. The FDA approved the first generic buprenorphine/naloxone sublingual films from Mylan and Dr. Reddy's in June 2018, with Alvogen, Sandoz, and Amneal following soon after. Generic buprenorphine/naloxone now costs about $30 to $300 per month in 2026, compared to $177 to $570 per month for brand-name Suboxone film. Most prescribers and pharmacies default to the generic unless there is a specific clinical reason to use the brand.
How do I apply for the Suboxone patient assistance or copay savings program?
Indivior discontinued its income-based free-medication program for uninsured patients once generics made cash prices affordable. Today, commercially insured patients apply for the INSUPPORT copay savings card at insupport.com or by calling 1-844-467-8778, which caps your copay near $5 per month. Uninsured patients get more value from generic buprenorphine/naloxone at a discount pharmacy price, a NeedyMeds discount card, or a sliding-scale Opioid Treatment Program found through findtreatment.gov.
Can I use the Suboxone savings card with Medicare or Medicaid?
No. Federal anti-kickback law prohibits Indivior's manufacturer copay card from being used by anyone with Medicare, Medicaid, TRICARE, or VA benefits. If you have Medicare, your Part D plan covers Suboxone with a formulary tier copay typically under $13 per month in 2026. If you have Medicaid, federal law requires coverage in every state, usually for $0 to $4 per prescription.
What if my insurance denies coverage for Suboxone?
Request the written denial notice and file a formal appeal within your plan's deadline, usually 60 to 180 days. Ask your prescriber to submit a peer-to-peer review explaining medical necessity, especially if the plan is requiring step therapy with a different formulation first. If the appeal is denied again, you can request an external review through your state's insurance regulator. Because generic buprenorphine/naloxone is inexpensive, paying cash at $30 to $100 per month is often faster than a prolonged appeal.
Does the Inflation Reduction Act's Maximum Fair Price apply to Suboxone?
No. Suboxone was not selected for Medicare's first or second round of drug price negotiation under the Inflation Reduction Act. CMS prioritizes high-cost, single-source brand drugs for Maximum Fair Price negotiation, and Suboxone has had generic competition since 2018, which already keeps prices low without negotiation. Your out-of-pocket protection instead comes from the general 2026 Medicare Part D annual out-of-pocket cap of $2,100.
What does Suboxone cost without insurance at the pharmacy counter in 2026?
Generic buprenorphine/naloxone costs roughly $30 to $100 per month with a GoodRx coupon at Walmart or CVS, and up to $300 per month without any discount, depending on dose and pharmacy. Brand-name Suboxone film runs $177 to $570 per month in cash. Always ask your pharmacist whether they carry the generic and whether a discount card like GoodRx or NeedyMeds applies before paying full retail.
Do I qualify for a Suboxone patient assistance program?
Indivior no longer runs an income-based free-drug program for Suboxone specifically. Instead, uninsured and low-income patients typically qualify for sliding-scale or free treatment at SAMHSA-funded Opioid Treatment Programs, searchable at findtreatment.gov, or simply pay the low generic cash price with a discount card. Commercially insured patients can qualify for the INSUPPORT copay card regardless of income.
What is the difference between Suboxone, Subutex, Sublocade, and Zubsolv?
Suboxone, Zubsolv, and Bunavail are all sublingual buprenorphine/naloxone combination products for daily self-administered opioid use disorder treatment, priced similarly at the pharmacy counter. Subutex is buprenorphine alone, without naloxone, and is used less often today. Sublocade is a different formulation entirely, a once-monthly extended-release buprenorphine injection given by a healthcare provider, billed under Medicare Part B rather than Part D, and typically costs far more per month than sublingual generics.
